Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Preclinical efficacy of sclerostin MAbs in increasing BMD and strength in OVX rats and monkeys

Oct. 6, 2006

New antidiabetic agents imparted in recent patent literature

Oct. 5, 2006

Hematopoietic-stimulating properties of HE-3210

Oct. 5, 2006

S-44029, a novel ADAM inhibitor, blocks osteoclastogenesis in vivo

Oct. 5, 2006

Inhibiting cathepsin K: effective blockade of bone resorption. Part II: preclinical activity

Oct. 5, 2006

Alista has potential in female sexual arousal disorder

Oct. 4, 2006

FM-VP4 completes phase II study in hypercholesterolemia

Oct. 4, 2006

Long-term ibandronate findings in postmenopausal osteoporosis presented

Oct. 4, 2006

FDA requests additional trial to support approval of ruboxistaurin mesylate

Oct. 4, 2006

Inhibiting cathepsin K: effective blockade of bone resorption. Part I: clinical activity

Oct. 4, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...